This regulatory mechanism unveils novel therapeutic avenues for hemoglobinopathies: Inhibiting TR2/TR4 activity or targeting their binding sites can reactivate HbF, alleviating erythroid pathological phenotypes in SCD [71,122]. Here, NR2C1 is linked to Schnyder corneal dystrophy.